FILED UNDER SOMETHINGISRAELI >> Health & Lifestyle
Think flu and an image of coughing and sneezing and generally feeling unwell springs to mind.
It costs business billions of dollars every year through people taking time off from work because they have a flu and are bedbound. Even worse with the new Avian Flu strain, it has the potential to cause the death of millions across the globe.
While there are vaccines in the market to deal with various flus, they are very specific and as soon as a flu develops a new strain, the old vaccine will not work.
But BiondVax, an Israeli company is working on a intra-nasal flu vaccine that aims to treat most types of flu and if proven, it could herald a new era in medicine.
Based around the idea of creating a universal flu vaccine as opposed to ones to treat specific conditions, research by BiondVax is the result of 20 years work by .Professor Ruth Arnon and her team at the Weizmann Institute. Professor Arnon has a long track record in developing medicine, she was involved with the team that developed the drug Copaxone used in treatment of multiple sclerosis.
Tests on animals are said to have been positive and the company hopes its product will be offered to the public within the next three years.
"We’re now beginning human clinical trials. We’re building a facility where we can conduct them," said BiondVax CEO Dr. Ron Babekof.
Dr Babekof says trails are already taking place on the dead virus with plans to work on a live virus. "We’ll have to move to safer conditions for trials on the live virus, because the virus is very deadly. We need a special laboratory, and we’re in touch with the Israeli State Veterinary Services concerning a joint trial with them," he added.
For more information: www.biondvax.com